Ingenol mebutate in actinic keratosis: a clinical, videodermoscopic and immunohistochemical study

Aged, 80 and over Male Dermoscopy Middle Aged Immunohistochemistry 3. Good health Keratosis, Actinic 03 medical and health sciences 0302 clinical medicine Humans Female Prospective Studies Diterpenes Aged
DOI: 10.1111/jdv.13831 Publication Date: 2016-07-25T06:16:45Z
ABSTRACT
AbstractBackgroundActinic keratosis (AK) is a cutaneous intraepithelial neoplasm that typically develops on sun‐damaged skin. The incidence of AK is increasing worldwide, and it is accepted as the most frequent pre‐malignant lesion in humans.ObjectivesTo demonstrate that ingenol mebutate gel is effective in the treatment of actinic keratoses because of its clinical, dermoscopic, capillaroscopic, histopathological and immunohistochemical treatment outcomes.MethodsSixty individuals with multiple non‐hypertrophic AKs were enrolled into this non‐randomized, open‐label, prospective, trial. Acquisition of clinical, dermoscopic and capillaroscopic images at baseline (T0), immediately after treatment on 3rd (trunk and/or extremities) or 4th (scalp and/or face) day (T1), 14 days after the end of the treatment (T2) and at 60 days (T3). A subgroup of 20 patients received a cutaneous biopsy both at baseline and at T3 for histological and immunohistochemical evaluation.ResultsClinical improvement was observed in 100% of cases: total clearance in 41 patients (68.3%); partial clearance in 19 patients (32.7%). After treatment, dermoscopic improvement of all non‐pigmented and pigmented AK lesions was observed. Most of the dermoscopic features disappeared with treatment. Total disappearance of specific vascular structures or significant reduction in the number and calibre of new blood vessels was capillaroscopically observed in all patients analysed (P ≤ 0.001). The immunohistochemical expression of p63 (P = 0.002), Ki‐67 (P = 0.015) and VEGF (P = 0.016) significantly decreased.ConclusionsThe clinical efficacy of ingenol mebutate on AKs is confirmed by its effect on angiogenesis, stem cell activity and cell proliferation in vivo.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (16)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....